Panamerican Journal of Trauma, Critical Care & Emergency Surgery

Register      Login

VOLUME 12 , ISSUE 3 ( September-December, 2023 ) > List of Articles


Descriptive Analysis of Thromboembolic Events in COVID-19 Patients in Qatar

Ahmed F Ramzee, Ayman El-Menyar, Mohammad Asim, Hassan Al-Thani, Fakhar Shahid, Areen Fino, Yaser M Ata, Hamzah El Baba, Arun P Nair, Muna S Al Maslamani, Ruben Peralta, Sandro Rizoli

Keywords : Coronavirus disease of 2019, Epidemic, Infarction, Infection, Qatar, Thromboembolic

Citation Information : Ramzee AF, El-Menyar A, Asim M, Al-Thani H, Shahid F, Fino A, Ata YM, El Baba H, Nair AP, Al Maslamani MS, Peralta R, Rizoli S. Descriptive Analysis of Thromboembolic Events in COVID-19 Patients in Qatar. Panam J Trauma Crit Care Emerg Surg 2023; 12 (3):120-130.

DOI: 10.5005/jp-journals-10030-1436

License: CC BY-NC 4.0

Published Online: 30-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Background: Current literature shows an increased risk of thromboembolic events (TEE) with coronavirus disease of 2019 (COVID-19) infection, possibly due to a unique interplay between the virus and the coagulation system. Materials and methods: A retrospective observational study of all patients with COVID-19 infection in the State of Qatar between February and August 2020 was performed. Analysis of all patients with TEE was carried out to identify other potential inciting factors for TEE. Results: There were 210 out of 16,903 (1.2%) patients with COVID-19 infection who developed TEE. Myocardial infarction (MI) was the most common event (76.2), with 11% deep vein thrombosis (DVT) and <10% with pulmonary embolism (PE), stroke, and other thrombotic events. Conclusion: Our study showed a low incidence of TEE compared to current literature. Patients with a previous history of thrombotic events were at a higher risk of developing a second event. Other significant contributing factors may have had a role in the development of TEE in the rest of the group. This questions the current belief that COVID-19 significantly increases the risk of TEE in the healthy population.

  1. COVID-19 Map. Coronavirus COVID-19 Global Cases by the Center for Systems Science and. Engineering (CSSE) at Johns Hopkins University (JHU). (2021). Accessed: May 15, 2020:
  2. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395(10231):1225–1228. DOI: 10.1016/S0140-6736(20)30627-9
  3. Luo Y, Li Y, Dai J. Low blood sodium increases risk and severity of COVID-19: a systematic review, meta-analysis and retrospective cohort study. medRxiv 2020. DOI: 10.1101/2020.05.18.20102509
  4. Roberts CM, Levi M, McKee M, et al. COVID-19: a complex multisystem disorder. Br J Anaesth 2020;125(3):238–242. DOI: 10.1016/j.bja.2020.06.013
  5. Klok F, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148–150. DOI: 10.1016/j.thromres.2020.04.041
  6. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18(8):1995–2002. DOI: 10.1111/jth.14888
  7. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in covid-19 patients: awareness of an increased prevalence. Circulation 2020;142(2):184–186. DOI: 10.1161/CIRCULATIONAHA.120.047430
  8. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021;76(10):970–979. DOI: 10.1136/thoraxjnl-2020-215383
  9. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135(23):2033–2040. DOI: 10.1182/blood.2020006000
  10. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020;50(1):72–81. DOI: 10.1007/s11239-020-02138-z
  11. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of. Health. Available at Accessed [27/08/2020]
  12. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18(6):1421–1424. DOI: 10.1111/jth.14830
  13. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021;76(4):412–420. DOI: 10.1136/thoraxjnl-2020-216243
  14. Campbell CM, Kahwash R. Will complement inhibition be the new target in treating covid19-related systemic thrombosis? Circulation 2020;141(22):1739–1741. DOI: 10.1161/CIRCULATIONAHA.120.047419
  15. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, et al. The role of anticoagulation in covid-19-induced hypercoagulability. Curr Cardiol Rep 2020;22(7):53. DOI: 10.1007/s11886-020-01328-8
  16. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20(10):1135–1140. DOI: 10.1016/S1473-3099(20)30434-5
  17. Cipolloni L, Sessa F, Bertozzi G, et al. Preliminary post-mortem covid-19 evidence of endothelial injury and factor VIII hyperexpression. Diagnostics (Basel) 2020;10(8):575. DOI: 10.3390/diagnostics10080575
  18. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021;398(10300):599–607. DOI: 10.1016/S0140-6736(21)00896-5
  19. Lopes RD, de Barros E Silva PGM, Furtado RHM. ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomized, controlled trial. Lancet 2021;397(10291):2253–2263. DOI: 10.1016/S0140-6736(21)01203-4
  20. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–1099. DOI: 10.1111/jth.14817
  21. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008;122(6):743–752. DOI: 10.1016/j.thromres.2006.10.026
  22. Iba T, Connors JM, Spyropoulos AC, et al. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? Int J Hematol 2021;113(3):330–336. DOI: 10.1007/s12185-021-03078-x
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.